Acumen Pharmaceuticals Q2 EPS $(0.28) Beats $(0.36) Estimate
Portfolio Pulse from totan@benzinga.com
Acumen Pharmaceuticals reported Q2 losses of $(0.28) per share, beating the analyst consensus estimate of $(0.36) by 22.22 percent. However, this is a 12 percent increase in losses compared to the same period last year.
August 08, 2023 | 11:02 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Acumen Pharmaceuticals' Q2 losses were less than expected, but increased compared to last year.
While Acumen Pharmaceuticals beat analyst estimates for Q2, the increase in losses compared to the same period last year could potentially offset any positive sentiment. The impact on the stock price is uncertain in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100